Workflow
OraSure Technologies(OSUR)
icon
Search documents
Is OraSure Technologies (OSUR) a Great Value Stock Right Now?
ZACKS· 2024-11-12 15:45
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value ...
OraSure Technologies (OSUR) Reports Q3 Loss, Tops Revenue Estimates
ZACKS· 2024-11-07 00:00
Company Performance - OraSure Technologies reported a quarterly loss of $0.01 per share, better than the Zacks Consensus Estimate of a loss of $0.04, and a significant decline from earnings of $0.27 per share a year ago, indicating a 103.7% decrease year-over-year [1] - The company achieved revenues of $39.92 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 1.97%, but down from $89.19 million in the same quarter last year, reflecting a 55.2% decline [2] - Over the last four quarters, OraSure has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - OraSure shares have declined approximately 47.7% since the beginning of the year, contrasting with the S&P 500's gain of 21.2% [3] - The current Zacks Rank for OraSure is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $38.51 million, while for the current fiscal year, the estimate is $0.05 on revenues of $186.12 million [7] - The outlook for the Medical - Products industry, to which OraSure belongs, is currently in the top 36% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]
OraSure Technologies(OSUR) - 2024 Q3 - Quarterly Results
2024-11-06 21:07
| --- | |--------------------------| | | | | | Investor Contact: | | Jason Plagman | | VP, Investor Relations | | investorinfo@orasure.com | Communications EXHIBIT 99.1 | --- | |---------------------| | | | | | | | Media Contact: | | Amy Koch | | Director, Corporate | | media@orasure.com | OraSure Reports Q3 '24 Revenue of $39.9 Million Q3 GAAP EPS of $(0.06); Q3 Non-GAAP EPS of $(0.01) OraQuick® HCV Self-test receives initial orders following receipt of WHO pre-qualification status Expanding Sample Managem ...
OraSure Reports Q3 '24 Revenue of $39.9 Million
GlobeNewswire News Room· 2024-11-06 21:05
Q3 GAAP EPS of $(0.06); Q3 Non-GAAP EPS of $(0.01) OraQuick® HCV Self-test receives initial orders following receipt of WHO pre-qualification status Expanding Sample Management applications into blood proteomics Exiting Risk Assessment testing business to focus on markets with attractive growth opportunities BETHLEHEM, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced its fina ...
OraSure: An NCAV Diamond In The COVID Rough
Seeking Alpha· 2024-11-04 14:32
OraSure Technologies Inc. (NASDAQ: OSUR ), a health and wellness company based in Pennsylvania, is a classic Benjamin Graham-style net current asset value-based investment (NCAV). While the discount to NCAV is only slight, it is perhaps worth the price due toI am a value investor with a concentrated portfolio, focusing on rare and exceptional buying opportunities. As a keen reader of Value Investing literature, I am well versed in the teachings of 'super investors' such as Warren Buffett, Charlie Munger, Be ...
OraSure to Announce Third Quarter 2024 Financial Results and Host Earnings Call on November 6th
GlobeNewswire News Room· 2024-10-22 20:05
BETHLEHEM, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2024 financial results and certain business developments for 5 p.m. ET on November 6, 2024. A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 1 ...
Neuberger Berman Group LLC Expands Stake in OraSure Technologies Inc
GuruFocus· 2024-10-04 20:03
Overview of Neuberger Berman Group LLC - Neuberger Berman Group LLC is a prominent investment firm located in New York, managing an equity portfolio valued at approximately $121.8 billion, with significant holdings in technology and financial services sectors [2] - The firm's investment philosophy emphasizes long-term growth and value creation through in-depth research and global market trends [2] Recent Transaction - On September 30, 2024, Neuberger Berman acquired 3,927,692 shares of OraSure Technologies Inc at a price of $4.27 per share, reflecting an 8.73% increase in its previous stake [1] - This acquisition enhances Neuberger Berman's exposure to the healthcare sector, particularly in medical devices, aligning with its strategy to invest in high-growth sectors [6] Profile of OraSure Technologies Inc - OraSure Technologies operates in the medical devices industry, focusing on diagnostic and molecular solutions for diseases such as HIV, HCV, and COVID-19 [4] - The company has a market capitalization of $308.717 million, with a current stock price of $4.14, indicating it is modestly overvalued compared to its GF Value of $3.51 [4] Financial Health of OraSure Technologies Inc - OraSure has a PE Ratio of 11.50, a return on equity (ROE) of 6.49%, and a return on assets (ROA) of 5.80%, indicating moderate efficiency in asset and equity utilization [5] - Despite a year-to-date stock price decline of 50%, the company has a three-year revenue growth rate of 28.90%, suggesting robust long-term growth potential [5] Market and Sector Outlook - The medical devices and instruments industry is expected to grow due to technological advancements and increasing healthcare demands globally [8] - OraSure is well-positioned to capitalize on these trends, despite current market undervaluations [8] Conclusion - Neuberger Berman's strategic increase in its stake in OraSure Technologies reflects a calculated move to strengthen its position in the healthcare sector, diversifying its portfolio and aligning with its long-term investment philosophy [9]
OraSure Technologies Elects Jack Kenny to the Board of Directors
GlobeNewswire News Room· 2024-09-09 11:05
BETHLEHEM, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions today announced the election of Jack Kenny to its Board of Directors, effective September 9, 2024. With the addition of Mr. Kenny, OraSure's Board of Directors currently has seven members. Mr. Kenny is the former Chief Executive Officer for Meridian Bioscience, where he led the company's turnaround before it was acquired. He has mor ...
OraSure Technologies (OSUR) Tops Q2 Earnings and Revenue Estimates
ZACKS· 2024-08-06 23:27
Core Viewpoint - OraSure Technologies (OSUR) reported quarterly earnings of $0.07 per share, exceeding the Zacks Consensus Estimate of $0.03 per share, and showing a significant improvement from a loss of $0.07 per share a year ago [1][2] Financial Performance - The company posted revenues of $54.34 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 1.86%, but down from $85.44 million in the same quarter last year [2] - Over the last four quarters, OraSure has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - OraSure shares have declined approximately 48.4% since the beginning of the year, contrasting with the S&P 500's gain of 8.7% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.01 on revenues of $40.22 million, and $0.04 on revenues of $188.7 million for the current fiscal year [7] - The estimate revisions trend for OraSure is mixed, which could change following the recent earnings report [6] Industry Context - The Medical - Products industry, to which OraSure belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting potential challenges ahead [8]
OraSure to Announce Second Quarter 2024 Financial Results and Host Earnings Call on August 6th
GlobeNewswire News Room· 2024-07-22 20:05
BETHLEHEM, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering second quarter 2024 financial results and certain business developments for 5 p.m. ET on August 6, 2024. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 ...